Protalix shareholders elect eight directors, approve advisory compensation, ratify auditor at annual meeting

Protalix BioTherapeutics, Inc.

Eight director nominees elected with for votes ranging from 21.3M to 22.6M; broker non-votes ~12.7M.
Non-binding advisory vote on named executive officer compensation passed: 16.4M for, 7.5M against, 0.4M abstain.
Ratification of Kesselman & Kesselman (PwC Israel) as independent auditor for 2025 approved: 34.9M for, 1.6M against.
Broker non-votes of ~12.7M present on director election and compensation proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.